• Products
  • Suppliers
  • Sourcing Requests
Post Sourcing Request Exhibition
Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising
New Products
3-Bromo-4-fluorobenzaldehyde
5-Methyl-1,3,4-oxadiazol2(3H)-one
4-Amino-6-methyl-3 oxo2,3, 4,5-tetrahydro 1.2.4-triazine hydrochloride
4-Acetylamino-6-methyl -3-oxo-2,3,4,5-tetrahydro-1,2,4-triazine
3-Pyridinecarboxaldehyde
Ethyl 3 Fluorobenzoate

Cuba grants emergency approval to second homegrown vaccine

firstwordpharmaAugust 23, 2021

Tag: Cuba , COVID-19 , Vaccine

Cuba's Center for State Control of Medicines, Equipment and Medical Devices granted emergency approval to the Soberana 2 vaccine for the prevention of COVID-19, as reported in National Post.

Cuba grants emergency approval to second homegrown vaccine

Approval means the vaccine, which is comprised of two initial shots and a booster, can be included in the national immunisation programme.

The Soberana 2 vaccine is said to have an efficacy rate of 91.2% and has already been used in Cuba to vaccinate some health workers and ordinary citizens in areas with high rates of transmission.


Previous:Vividion Therapeutics officially withdraws $100 million IPO following acquisition by Bayer

Next:Spotting the Signs of Deadly Melanoma Skin Cancers

Related News

BioPharmaSpec Announces Three New Facilities in Freiburg, Bergamo and Vilnius

Biotech NewswireNovember 20, 2024

BioPharmaSpec, the leading global Contract Research Organization (CRO) for Discovery and Preclinical Characterization of Biopharmaceuticals, has officially announced three new European facilities.

Rona Therapeutics Presented Positive Phase 1 Results of RN0191, a Novel siRNA Therapy Targeting PCSK9, at the 2024 American Heart Association (AHA) Scientific Sessions

PR NEWSWIRENovember 20, 2024

AI in Pharmacovigilance: Predicting & Preventing Drug Risks

Nurah EkhlaqueNovember 19, 2024

Cuba grants emergency approval to second homegrown vaccine | Pharmasources.com

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

PharmaSourcesNovember 15, 2024

InnoCare Announces First Subject Dosed in the Phase III Registrational Trial of TYK2 Inhibitor ICP-332 for the Treatment of Atopic Dermatitis in China

You may like
More>>

Heating Incubator(natural convection)

Heating Incubator(natural convection)
H7N9 Inactivated Influenza Vaccine

H7N9 Inactivated Influenza Vaccine
Poultry Vaccine Series 2

Poultry Vaccine Series 2
OPV(Poliomyelitis(Live)Vaccine(Monkey Kidney Cell).Oral

OPV(Poliomyelitis(Live)Vaccine(Monkey Kidney Cell).Oral
Hualan's Influenza Vaccine

Hualan's Influenza Vaccine
Influenza Vaccine(Split Virion),Inactivated manufactured by Hualan Bio

Influenza Vaccine(Split Virion),Inactivated manufactured by Hualan Bio
Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)

Hualan Biological Recombinant Hepatitis B Vaccine (Hansenula polymorpha)
2023-2024 Recommended composition flu vaccine

2023-2024 Recommended composition flu vaccine
Thermo Shaker Incubator SMS200

Thermo Shaker Incubator SMS200
H7N9 Inactivated Influenza Vaccine by hualan biological

H7N9 Inactivated Influenza Vaccine by hualan biological

Contact Us

PharmaSources@imsinoexpo.com

Tel: (+86) 400 610 1188

WhatsApp/Telegram/Wechat: +86 13621645194

About Us
About PharmaSources
Terms of Service
Privacy Policy
Intellectual Property
Media Partners
Buy
Search Products
Post Sourcing Requests
Search Suppliers
CAS Search
Sell
Member Application
Advertising
Post Products
EZSourcing
Events
CPHI China
PMEC China
Conferences
Search Events
Help
FAQ
Contact Us
Feedback
PharmaSources Customer Service